Companies/US/ACAD

ACADIA PHARMACEUTICALS INC.

Income flow

Annual
ACAD 10-K Income StatementPeriod 2025-12-31Source 10-K
Reportable Segment Aggregation Before Other Operating Segment$1BRevenue$1B+12% Y/YGross profit$983M+12% Y/YCost of revenue$89MOperating profit$105M-55% Y/YOperating expenses$878MNet profit$391M+73% Y/YSG&A$549MR&D & other$329M

As-filed revenue segments and annual P&L (gross, opex, tax, net). Layout inspired by SankeyArt finance diagrams.

Revenue mix

2025-12-31 · 10-K · USD
By activity
By activity$1.1B
  • Reportable Segment Aggregation Before Other Operating Segment$1.1B100.0%

Capital & dividends

YieldTrailing twelve-month dividends as a percent of the current share price (income yield).0.00%Trailing DPSCash dividends paid per share over the last twelve months (dividend per share, trailing).0PayoutShare of earnings paid out as dividends. Higher means more income returned; lower leaves more for reinvestment.0.0%Shares outTotal shares currently outstanding (issued and not retired).172.3MFloatShares available to trade — outstanding minus closely held (insiders, strategic holders).128.4M

Valuation

Trailing PE 11.6 (2025-12-31)PE trend

Fiscal PE2

PeriodEPSClosePE
2025-12-312.326.7111.6
2024-12-311.3618.3513.5

PE = stored close ÷ as-filed diluted EPS (annual 10-K / 20-F). Not a vendor PE series.